The INTRIGUE study is testing the investigational drug DCC-2618 as a potential new treatment option for patients living with gastrointestinal stromal tumors (GIST). The study is being done to learn more about the safety of DCC-2618 and how well it works against cancer, as compared to Sutent® (sunitinib), in patients who have previously received imatinib.